Abstract 16632: Post-Market Adverse Events of the OmniaSecure Defibrillation Lead: A Manufacturer and User Facility Device Experience Analysis
Post-Marketing-Nebenwirkungen des OmniaSecure-Defibrillationskatheters: Analyse von Hersteller- und Anwenderberichten
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.16632 ↗Auf einen Blick
In 203 einzigartigen Post-Market-Berichten zu OmniaSecure waren Oversensing und weitere Sensing-Störungen die häufigsten gemeldeten Probleme. Berichte zur Reizleitungssystem-Implantation zeigten häufig Oversensing, ohne gemeldete Todesfälle.
Fragestellung
Welche Post-Market-Nebenwirkungen wurden für den OmniaSecure-Defibrillationskatheter in MAUDE berichtet, insgesamt und nach Implantationsort?
Methode
Analyse von MAUDE-Berichten zu OmniaSecure von April 2025 bis Juni 2026; Einteilung nach Reizleitungssystem-, RV- oder unklarer Platzierung anhand der Narrativangaben.
Ergebnisse
203 einzigartige Berichte: 110 Malfunktionen, 90 Verletzungen, 3 Todesfälle. Oversensing 102 (50,2 %), Undersensing/decreased sensing 30 (14,8 %), Capture-/Schwellenprobleme 30 (14,8 %), Dislokation/Migration 27 (13,3 %).
Einschränkungen
MAUDE hat keinen Nenner; die Proportionen spiegeln gemeldete Ereignisse, nicht die Inzidenz.
Schlussfolgerung der Autor:innen
In der frühen Post-Market-Überwachung dominierten Oversensing und andere Sensing-Abnormalitäten. Die Autor:innen betonen, dass reale Ergebnisse von kontrollierten Studien abweichen können und weitere Überwachung nötig ist.
Kernaussagen
- 203 einzigartige Post-Market-Berichte wurden ausgewertet
- Oversensing war das häufigste Problem (102; 50,2 %)
- Bei Reizleitungssystem-Implantation wurden 56 Berichte identifiziert; keine Todesfälle
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Divyasri Koneru und 2 weiteren Autor:innen.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
OmniaSecure is a 4.7-Fr lumenless transvenous defibrillation lead and the first defibrillation lead to receive FDA approval for left bundle branch area (LBBA)/conduction-system placement. In the LEADR pivotal trial (n = 643), freedom from major lead-related complications was 96.5% at 3 years with zero fractures; LEADR LBBAP trial (n = 307) reported 97.9% freedom from major complications at 3 months. Given historical concerns regarding small-diameter ICD lead performance, early real-world post-market surveillance is warranted.
Methods
We queried the FDA Manufacturer and User Facility Device Experience (MAUDE) database for medical device reports (MDRs) involving the OmniaSecure lead received from April 2025 through June 2026. Lead placement was classified as conduction-system placement (LBBA/His), right ventricular (RV), or unclear based on explicit narrative evidence. Because MAUDE lacks a denominator, proportions reflect reported events rather than incidence.
Results
We identified 218 MDRs; after excluding 4 duplicate clinical event reports and 11 clinical-study reports, 203 unique post-market reports were analyzed: 110 malfunctions, 90 injuries, and 3 deaths. The most common reported problem was oversensing (102; 50.2%), followed by undersensing/decreased sensing (30; 14.8%), capture and/or threshold problems (30; 14.8%), and dislodgement/migration (27; 13.3%). Lead integrity/fracture/stretch concerns were reported in 12 MDRs (5.9%) and inappropriate shocks in 7 (3.4%). Narrative-confirmed conduction-system placement was identified in 56 MDRs (27.6%), including 54 LBBA/LBBAP and 2 His-bundle; 132 RV-only and 15 unclear/multi-lead. Oversensing was reported in 34/56 (60.7%) conduction-system vs 67/132 (50.8%) RV-only reports (OR, 1.50; 95% CI, 0.79-2.83). No deaths were reported among conduction-system placement MDRs. Among 3 death reports, 2 involved RV-placed leads with sensing-related concerns; the third was reported as unrelated to device function.
Conclusion
In early post-market surveillance, oversensing and broader sensing abnormalities were the dominant reported problems, with additional reports of dislodgement, capture/threshold problems, lead integrity concerns, and inappropriate shocks. The high prevalence of oversensing contrasts with zero oversensing events in the LEADR LBBAP trial, suggesting real-world performance may differ from controlled trial settings. Reports involving the conduction-system showed frequent oversensing without reported deaths to date. This analysis underscores the need for continued post-market surveillance and prospective evaluation of OmniaSecure performance in both RV and conduction-system placement.
Zitieren
APA
Koneru, D., Polana, V., & Talupula, R. M. (2026). Abstract 16632: Post-Market Adverse Events of the OmniaSecure Defibrillation Lead: A Manufacturer and User Facility Device Experience Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.16632
Vancouver
Koneru D, Polana V, Talupula RM. Abstract 16632: Post-Market Adverse Events of the OmniaSecure Defibrillation Lead: A Manufacturer and User Facility Device Experience Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.16632
BibTeX
@article{Koneru2026,
author = {Koneru, Divyasri and Polana, Viswanadh and Talupula, Ram Manohar},
title = {Abstract 16632: Post-Market Adverse Events of the OmniaSecure Defibrillation Lead: A Manufacturer and User Facility Device Experience Analysis},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.16632}
}
EUVIMED